Decades of research have shown that mutations in BRCA1, BRCA2, and other genes involved in homologous recombination (HR) are significant prognostic indicators for survival and response to platinum-based therapy in ovarian cancer [24,25]. This evidence concerns the gene BRCA2 and ovarian carcinoma.